Navigation Links
Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
Date:11/15/2012

RARITAN, N.J., Nov. 15, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen R&D) today announced the establishment of a global cross-pharmaceutical Investigator Databank designed to improve efficiencies of industry-sponsored clinical trials. Merck and Eli Lilly and Company are the first two companies to join Janssen in this effort. 

(Logo: http://photos.prnewswire.com/prnh/20120117/LA36598LOGO)

The new Investigator Databank, established as part of this novel industry collaboration, will serve as a one-stop repository where key information about clinical trial sites, such as infrastructure and Good Clinical Practice (GCP) training records, is housed. This will allow participating pharmaceutical companies to reduce time-consuming and sometimes redundant administrative work involved in identifying appropriate clinical trial sites.   

At the outset of every clinical trial, pharmaceutical companies initiate clinical trial site selection, prequalification and GCP training, which can be paperwork-heavy and time-consuming for trial sponsors and investigators alike. By housing critical information about investigators and trial sites in one place, the databank will reduce time, cost and duplicative efforts, making it easier for companies to identify appropriate trial sites and investigators for future clinical trials. Investigator sites that have opted-in to data sharing will have their relevant information accessible to pharmaceutical companies participating in the collaboration. This databank will not include any patient data.   

"The current clinical trial environment is inefficient, costly and unsustainable. The Investigator Databank can help expedite the process to achieve our most important goal – to deliver high-quality, effective novel medicines to the patients who are waiting for
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
10. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
11. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)...  Sanofi (EURONEXT: SAN and NYSE: SNY ) ... , examining the selective JAK2 inhibitor SAR302503 for ... groups. The primary endpoint assessed the proportion of patients ... reported in previous trials, the most common adverse events ... be presented at an upcoming medical congress. ...
(Date:5/17/2013)...  Boston Scientific Corporation (NYSE: BSX ) ... Program May 21-24 in Paris . ... rich and diversified set of data this year at ... global chief medical officer, Boston Scientific.  "The primary endpoint ... NG PROMUS trial, which evaluated our Promus PREMIER ™ ...
(Date:5/16/2013)... , May 16, 2013  PTC Therapeutics, Inc., ... on Form S-1 with the U.S. Securities and Exchange ... of its common stock. The number of shares to ... have not been determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ... are acting as joint book-running managers for the offering. ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
... Patients with active moderate to severe rheumatoid arthritis ... or adalimumab (Humira ® ) and who were actively ... from baseline at week 10, and sustained response through ... 26 results from the RESTART study were presented for ...
... LLC, the image analysis and pattern recognition technology provider, ... of $244,479.25 under the U.S. Government,s Affordable Care Act. ... projects that show significant potential to produce new therapies, ... health care costs or advance the goal of curing ...
Cached Medicine Technology:New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 2New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 3New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 4New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 5New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 6New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 7Parascript Awarded $244,479.25 Affordable Care Act Grant From the U.S. Government 2
(Date:5/19/2013)... 2013 Minor fender benders and serious ... require parties to the accident to respond appropriately to ... and Prevention (CDC) data from 2010, accidents, including car ... In fact, in 2005, automobile accident-related deaths ... more than 2.3 million drivers and passengers receive treatment ...
(Date:5/19/2013)... Columbus, OH (PRWEB) May 19, 2013 ... LLC continue to follow developments in the nation’s first ... The case, underway in Washington State Superior Court, was ... several years after he suffered complications in a robot-assisted ... The Da Vinci robotic surgery lawsuit ...
(Date:5/18/2013)... COOLA, British Columbia (PRWEB) May 19, 2013 ... to Cooking” (published by iUniverse) , author Janet Hall Svisdahl’s ... delectable world recipes sure to make even the pickiest ... living peacefully, pleasurably and prayerfully,” she explains. , Found ... Spirit” are a wide range of delicious recipes, from fast ...
(Date:5/18/2013)... 19, 2013 The American Society for Gastrointestinal Endoscopy ... endoscopy during the ninth annual ASGE Crystal Awards on ... ASGE Foundation, this year,s event will begin at ... Fla. , Held in conjunction with Digestive Disease ... in leadership, research and scientific pursuit. The event will ...
(Date:5/18/2013)... Bethesda, MD (May 19, 2013) The American ... announce its 2013 research scholars. This year,s honorees ... in gastroenterology, hepatology or related areas, and with ... , "These young researchers are the future ... young scholars who are paving the way for ...
Breaking Medicine News(10 mins):Health News:Auto Accident Infographic Issued by d’Oliveira & Associates on Steps to Take After a Car Crash 2Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 2Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 3Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 4Health News:Janet Hall Svisdahl Announces Release of ‘Cooking with Spirits for the Spirit’ 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 3Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 4Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 5Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 6Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 7Health News:AGA Research Foundation Research Scholar Awards advance the work of promising gastroenterologists 2
... a specialty,bank consulting firm, has moved its affiliation to ... independent office of,John Hancock Financial Network in Buffalo, NY, ... to the entire network nationally,announced Peter Gordon, President of ... are excited to be able to offer this specialized ...
... In a statewide survey of medical professionals, 38 physician-scientists ... Medical Center (LA BioMed) are honored for being ... issue of Los Angeles magazine. , Key Professional Media, ... professionals to compile the 2008 list of Southern California ...
... of West,Virginia, Inc. and the Nitro Walmart Marketplace are working ... significant,increase for unexpected emergency needs assistance. , ... events, being held this Friday and,Saturday, more than $20,000 in ... food that will help thousands of area families pay bills, ...
... Clinically Proven, Anti-Aging REVALESKIN(R) Skin Care Brand Launches ... and REVALESKIN(R) Chest/Decolletage Rejuvenating Treatment, All Exclusively Formulated ... , CORAL GABLES, ... of the extraordinarily successful introduction of the core ...
... , , NEW YORK, Dec. 4 ... that it has repurchased 640,930 shares of WebMD Class A Common ... LLC, which was acquired by WebMD in December 2006. In ... in cash pursuant to the terms of the previously completed Subimo ...
... Dec. 4 The Perrigo Company,(Nasdaq: PRGO ... Desloratadine tablets (5 mg) has been settled with Perrigo ... been sued for patent infringement of,US Patent Nos. 6100274, ... ANDA,containing a Paragraph IV certification. Under the terms ...
Cached Medicine News:Health News:John Hancock Financial Network Offers Bank Owned Life Insurance Resource to Its Independent Career Firms Nationally 2Health News:John Hancock Financial Network Offers Bank Owned Life Insurance Resource to Its Independent Career Firms Nationally 3Health News:LA BioMed researchers among Southern California Super Doctors 2Health News:UniCare, Walmart Organize Circle of Hope To Help Mountain Mission Meet Increased Demand for Assistance 2Health News:Stiefel Laboratories Announces the Expansion of Its REVALESKIN(R) Skin Care Line With Three New Products 2Health News:Stiefel Laboratories Announces the Expansion of Its REVALESKIN(R) Skin Care Line With Three New Products 3Health News:Stiefel Laboratories Announces the Expansion of Its REVALESKIN(R) Skin Care Line With Three New Products 4Health News:Stiefel Laboratories Announces the Expansion of Its REVALESKIN(R) Skin Care Line With Three New Products 5Health News:Stiefel Laboratories Announces the Expansion of Its REVALESKIN(R) Skin Care Line With Three New Products 6Health News:WebMD Announces Repurchase of 640,930 of its Shares 2Health News:Perrigo Settles Desloratadine Patent Litigation 2Health News:Perrigo Settles Desloratadine Patent Litigation 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: